Engaging Thought Leadership
Over 50 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
Biomarkers Europe 2024
30 September - 01 October 2024 | Basel, Switzerland
Gain insights into Biomarker approaches & accelerate timelines in drug development for oncology and immuno-related therapies
Biomarkers Europe 2024
Meet Our Expert Speakers
The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Biomarkers Europe 2024: 30 September - 01 October 2024, Basel, Switzerland
Benjamin Weber
Vice President Translational Research,
Novo Nordisk
Brian Lockhart
Global Heaf of Companion Diagnostics,
Servier
Ed Schuuring
Clinical Scientist in Molecular Pathology,
umcg
Gunther Jansen
Head of Multimodal Data & Analytics,
Novartis
Joanna Janus
Research Programme Manager (Early Detection and Prevention),
Cancer Research UK
Olga Nissan
CEO,
Protica Bio
All Speakers
Amanda Heslegrave
Senior Research Fellow,
University College London
Axel Ducret
expert scientist,
F. Hoffmann-La Roche Ltd
Bernhard Reis
Biomarker Lead,
F. Hoffmann-La Roche Ltd.
Bernhard Reis
Expert Biomarker & Translational Medicine Leader; Group Head Biomarker Strategy,
F. Hoffman-La Roche Ltd.
Christian Ruiz
Senior Lecturer; Chief Scientific Officer,
University of Basel; Moonlight AI
Cornelia Wilson
Reader and Academic Laboratory Director,
Canterbury Christ Church University
Dylan Powell
Lecturer Public Health and Innovation,
Stirling University
Fatima Sanfourche
Senior Director of QA & RA Compliance for Medical Devices and eHealth,
Bayer
Gro Live Fagereng
Project Manager of the EU-project PRIME-ROSE and Coordinator Precision Cancer Medicine at OUH Centre for Precision Cancer Medicine,
Oslo Universitetssykehus
Guillaume Desachy
Head Of Biometrics,
Pierre Fabre
Jacques Colinge
Professor,
University of Montpellier, France
Jehad Charo
Principal scientist - Biomarker Experimental Medicine Leader,
Hoffmann La Roche Ltd
Jon Krell
Senior Clinical Lecturer and Honorary Consultant in Medical Oncology,
Imperial College London
Jose MG Izarzugaza
Head of Department,
Novo Nordisk
Karolin Rommel
Biosample Project LEader,
F. Hoffmann-La Roche Ltd
Maximilian Breitner
Laboratory Head Bioanalytics,
Sandoz
Michael Cannarile
Expert Biomarker & Translational Medicine Leader; Group Head Biomarker Strategy,
China Innovation Center of Roche
Nolwen Guigal-Stephan
Head of Clinical Biomaker Development,
Servier Monde
Shashank Saran
associate director,
Not applicable
Meet Our Esteemed Sponsors
Platinum Sponsors
Gold Sponsors
Silver Sponsors
.png?length=600&name=images%20(2).png)
Abcam PLC
Silver Sponsor
At abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.
Seer
Silver Sponsor
Seer develops innovative solutions that act as a gateway to the proteome. Our products are designed to accelerate the pace of proteomics by removing the technological barriers that stand between you and the proteomics you want to do. The Proteograph platform enables unbiased, deep, rapid, large-scale proteomics studies – the kind needed to advance our understanding of biology, health, and disease. It is now possible to accurately survey and analyze the full diversity of proteins across individuals, over time. Our goal is to empower the scientific community with tools for exceptional proteomics outcomes.
Bronze Sponsors
.jpg?length=600&name=d7563f0d-f009-49cd-8a2d-f682a079a3bb-2-5668375logo-ICON-Positive-logo-JPEG(nostrap).jpg){kind=icon}
ICON Clinical Research Ltd
Bronze Sponsor
ICON is the world’s leading clinical research organisation, powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employs approximately 41,150 employees in 113 locations in 53 countries. For further information, visit www.iconplc.com
Network & Programme Sponsors
Concept Life Sciences
Network & Programme Sponsor
Concept Life Sciences, a collaborative client-centred approach. We are a multi-disciplined Contract Research Organisation based in the UK providing market-leading scientific services globally. Over the past 25 years, Concept Life Sciences and its heritage companies have played a pivotal role in guiding numerous clients along their path to clinical success and many of these clients have evolved into enduring scientific collaborators. Within a decade, the collaborative efforts of experts from our heritage businesses — Peakdale Molecular, CXR Biosciences, and Aquila Biomedical — have propelled us beyond the cumulative impact of our individual components, fostering substantial growth and advancement. We are based across 4 research sites in the UK delivering discovery research, as well as GMP, GLP, and GCP-regulated work. Whether it is delivering whole programs of research, or bespoke studies, we deliever a a collaborative client-centred approach. Our services include discovery chemistry, specialist translational biology for immunology, oncology and neuroscience, biologics, biophysical assays services, ADMET & DMPK, bioanalysis, toxicology, histology, analytical services, including materials characterisation and physiochemical analysis, process research and development, and GMP manufacturing.
Q2 Solutions- Rules Based Medicine
Network & Programme Sponsor
Rules-Based Medicine (RBM), a Q2 Solutions Company, is the world’s leading multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture®). RBM’s internally developed and manufactured immunoassays based on Multi-Analyte Profiling (MAP) and Single-Molecule Array (SimoaTM) ultrasensitive immunoassay technology provides translational and clinical researchers with reproducible and quantitative data for a few or hundreds of human proteins. The comprehensive menu provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments. RBM’s CLIA certified biomarker testing laboratory is located in Austin, TX. Q2 Solutions is a leading global clinical trial laboratory services organization providing bioanalytical, genomics, vaccines, flow cytometry, anatomic pathology, immunoassay, companion diagnostics and central laboratory services with secure, enterprise-wide biospecimen and consent management solutions. With our industry-leading science, partnership approach and innovative solutions, we’ll make sure our clients get the results that will turn patients’ hope into the help they need.
Sponsors of Biomarkers Europe 2023 included
10X Genomics
Bespoke Sponsorship
10x Genomics builds solutions to interrogate biological systems at a resolution and scale that matches the complexity of biology. Our end-to-end single cell and spatial solutions include instruments, consumables, and intuitive software, letting you unravel highly intricate biological systems, while bringing into focus the details that matter most.
APIS Assay Technologies
Silver Sponsor
APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility. APIS has deep expertise and capabilities in IVD development of molecular & immune-assays for ultimate product realisation as diagnostic tests. In addition, APIS' expertise in bioinformatics and software development is offered as an agile service to our clients, to develop bespoke, end-to-end multi-OMICs solutions and platform development. The new APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The new APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The kit has a wide target coverage of 11 different ESR1 mutations.
ARC Regulatory
Silver Sponsor
ARC Regulatory is a niche consultancy, offering global regulatory and clinical research solutions including being a full CRO to the precision medicine and in vitro diagnostic medical device industry. ARC’s mission is simple. From its headquarters in Northern Ireland, it supports companies, from the world’s top pharmaceutical and biotech leaders to medical device start-ups, in the search to find kinder patient treatments. By guiding customers through the complex, myriad of international regulatory and research requirements, ARC facilitates market access for new medical discoveries. ARC is proud to be a trusted partner in the global ambition to improve patient care, leveraging its team’s expertise in delivering high quality, accelerated clinical research for biomarker diagnostics. Learn more at www.arc-regulatory.com ARC Regulatory bietet spezialisierte Beratungsleistungen für die Erfüllung von regulatorischen Anforderungen in der klinischen Forschung, unter anderem als Full-Service CRO rund um personalisierte Medizin und In-Vitro Diagnostik (IVD). Das Firmenleitbild ist einfach: Von seinem Hauptsitz in Nordirland aus unterstützt ARC zahlreiche Kunden – von weltweit führenden Pharma- und Biotech-Unternehmen bis hin zu Start-ups im Bereich Medizintechnik – bei der Suche nach patientenfreundlicheren Behandlungen. ARC führt seine Kunden durch die vielen und komplexen internationalen regulatorischen Anforderungen und erleichtert somit den Marktzugang für neue medizinische Entwicklungen. Als ein vertrauenswürdiger Partner für die Verbesserung der globalen Patientenversorgung nutzt ARC die Expertise seines Teams und bietet somit die Grundlage für die hochwertige und beschleunigte Bearbeitung von klinischen Forschungsprojekten für die Biomarker-Diagnostik. Erfahren Sie mehr unter www.arc-regulatory.com
Bio-Rad Laboratories Ltd
Silver Sponsor
Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers include university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality.
Biognosys AG
Exhibition and Tech Demo Sponsor
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.
CellCarta
Silver Sponsor
Leading provider of specialized precision medicine laboratory services with integrated platforms in immunology, histopathology, proteomics, genomics, and related specimen collection and logistics services. CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials, and operates globally with laboratories in Canada, USA, Belgium, Australia, and China.
-(1).jpg?length=600&name=6a5ed8cc-2148-4274-994c-b38b2f129048-2-5668375logo-Company-Logo-2-(High-Vector)-(1).jpg){kind=logo}
Pixelgen
Bronze Sponsor
Pixelgen is at the forefront of innovative life science research tools. Pixelgen Technologies was founded on the principle that understanding how proteins move and relocate across the cell membrane is critical to better understanding cell activity. The company has developed a foundational IP portfolio around its Molecular Pixelation (MPX™) technology, which is the first technology to capture the dynamic changes that occur with the cell surface proteome at such a high multiplexed level on thousands of cells simultaneously. The Molecular Pixelation workflow connects antibody-based technologies and next generation sequencing to generate unprecedented resolution of protein activity and mobility. The first reagent kit product was launched this year, targeting the surface proteome of immune cells, enabling localization of 76 target proteins and four controls in 3D without the use of a microscope - but with high throughput and resolution. The MPX reagent kit is built on DNA sequence formation providing target identity, abundance and spatial location. Subcellular resolution is produced utilizing standard instrumentation for sequencing already present in most labs, thus allowing for barrier-free adoption for any researcher. Molecular Pixelation (MPX), is used by our customers to enable spatial proteomics of single cells gaining new insights into cellular activity and for drug development. Pixelgen was founded in 2020 by serial entrepreneurs behind multiple innovative products and companies in the life sciences and located in Stockholm Sweden, www.pixelgen.com.
Sengenics LLC
Silver Sponsor
Sengenics is an immunoproteomics company working to improve patient outcomes through biologically relevant, data-guided decision making. Our solutions enable the discovery and validation of immune protein biomarkers for patient diagnosis, therapeutic response prediction and stratification. Sengenics is a global research and development products company located in Greater Boston, MA USA, with offices and laboratories worldwide.
Tribun Health
Bronze Sponsor
Tribun Health, a prominent player in computational pathology, empowers scientists to accelerate drug development (DD) and perform more rapid diagnoses. Tribun is a privately owned, ISO 13485 certified company established in 2016 with 54 employees. Our mission is to revolutionize disease diagnostics and make precision medicine a reality to enhance patients' lives. Our key therapeutic focus areas are oncology and inflammatory diseases. We provide diverse software solutions to customers, making us a driving force behind digital transformation. The EyeDo Platform is dedicated to translational and clinical research. It is cloud-based, offering functionalities that enable customers to comply with GCLP regulations, including controlled workflows, audit trails, and E-signatures. The CaloPix Platform, dedicated to diagnostics, has received the "Best in Klass 2022 & 2023" awards as the most successful digital pathology provider in Europe. This product is utilized in over 200 hospitals and is available as a cloud solution or on-premises. It is an in-vitro medical device, both CE-IVD marked and Health Canada licensed. The US FDA submission is currently in progress. Teleslide is a web-based tool for pathologist second opinions and telemedicine. We prioritize cutting-edge technologies in our products and leverage AI to enhance accuracy and productivity. Our proprietary deep-learning pipeline of AI tools facilitates image translation into meaningful decisions, prognoses, and diagnoses. Models on different staining modalities from H&E and IHC to multiplex immunofluorescence are available, some of which are CE-IVD marked. The tools encompass tissue and cell segmentation, as well as classification in oncology and inflammatory diseases such as NASH. Models can be hosted on either platforms or approved third-party platforms. Our scalable products contribute to customer digital transformation acceleration as they are interoperable, facilitating interface with information systems to foster productive collaborations and accelerate time-to-insight for improved patient outcomes. We offer a range of Full Digital Services to cater to the needs of our customers. AI Assay Validation services involve AI tool customization using our proprietary pipeline of tools for customer-specific needs. AI Assay Run Services: Outsource your image analysis projects fully to us. Discovery Services: We use AI to extract meaningful insights from images. Findings come with heatmaps and morphological annotations to identify biomarkers and predictive signatures. Pathologist services: Benefit from the expertise of our certified pathologists for your image analysis projects. The executive team is led by its CEO, Jean-François Pomerol, who has been at the helm of Tribun since its foundation. He is supported by 10 executive members. The Scientific board consists of pathologists with extensive experience from world-renowned institutes. Strategic partnerships are highly valued, including the Cleveland Clinic and GE Healthcare, to name a few.
Ultivue
Silver Sponsor
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays and spatial image analysis for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.
Veracyte
Network & Programme Sponsor
Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. We provide novel insights, expertise and capabilities that empower our biopharmaceutical partners to confidently advance every step of their oncology drug development programs. We offer state-of-the-art assays, including Brightplex (Multiplex IHC) technology and genomic/transcriptomic analysis, all support by robust data analysis capabilities. These integrated services enable us to to provide in-depth insights into the complex tumor micro-environment. Supported by a team of experts, we empower biopharmaceutical companies to advance their oncology clinical trials and develop innovative cancer treatments.
New MND Early Diagnostic Test: a 'Game-Changer' for Research on the Disease
Detecting the aggregation of TDP-43 spells a new diagnostic tool for MND.
Enhancing Patient Care: Exploring the Role of Digital Biomarkers in Patient-Centric Healthcare
Digital biomarkers, collected from wearables and apps, are reshaping patient-centered healthcare with real-time insights and personalized care. Challenges like data privacy and interoperability require collaboration between healthcare, tech, and regulators for full integration.
How Digital Biomarkers Can Enhance Pathologies and Patient Care
Digital biomarkers hold promise for healthcare, offering improved rare disease detection and cost reduction, with the potential for future implementation in clinical healthcare settings.
How Multiplexing Could Increase the Availability of Blood Biomarkers for Classifying Neurodegenerative Disorders
Recent studies have used multiplex blood biomarker information from patients to distinguish individual patient subgroups for neurodegenerative diseases, helping to stratify patients by their pathology.
Biomarkers in Precision Medicine Approaches for Oncology: Overcoming Obstacles to Usage and Uptake
Precision medicine involves tailoring a therapeutic to a patient’s disease: developing precision therapies require an accurate identification of therapeutic targets from available data.
Lung Cancer Patient Response to Immunotherapy Could be Predicted Through AI-Calculated Biomarker
Breakthroughs in the use of AI for biomarker prediction and validation of efficacy could shape future treatments for immunotherapies. In this case study, we look at its applications in validating lung cancer patient responses to treatment.
Congress Center Basel
MCH Swiss Exhibition (Basel) Ltd.
Messeplatz 21, CH-4058 Basell
By Rail
Basel is an international rail hub with direct ICE, IC and EC connections to Germany, Austria, Italy, France and the Benelux countries. Messe Basel can be reached in five to ten minutes from the three railway stations in Basel: SBB (Switzerland), SNCF (France) (Frankreich) and DB (Badischer Bahnhof, Germany)
By Tram
From the SBB/SNCF railway station, it’s a ten-minute journey on the No. 1 or 2 Tram to the “Messeplatz/Exhibition Square” stop where Messe Basel and the Congress Center are located. From Badischer Bahnhof railway station, “Messeplatz/Exhibition Square” is the second stop on the No. 2 or 6 tram.
By Air
EuroAirport Basel-Mulhouse-Freiburg is 15 minutes by car from Messe Basel. Basel municipal transport’s No. 50 bus additionally provides a straightforward connection from the airport to the SBB/SNCF railway station. From there, tram No. 1 or 2 will take you directly to Messeplatz/Exhibition Square. From Zurich Airport a direct rail connection will bring you to the SBB/SNCF railway station in Basel in less than an hour. For further information including a map and full directions, please visit: https://www.messe-basel.com/en/about-us/getting-to-messe-basel/
By Car
Basel is located at the point where the Swiss, German and French motorway networks all meet. The exhibition and congress site has its own direct link to the A2 motorway. The “Messe” exit will take you straight to the Messe Basel car park with its 1,200 parking spaces.
Information regarding accommodation for this event will be added here soon
We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.
As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.
Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.
Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.
If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Biomarkers Europe 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.
